Drug Profile

Research programme : GPR75 modulators - Mwyngil Therapeutics/Expert Systems

Latest Information Update: 07 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Expert Systems
Class Antihyperglycaemics; Obesity therapies; Small molecules
Mechanism of Action GPR75 protein modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Obesity; Type 2 diabetes mellitus

Most Recent Events

02 Feb 2026 Mwyngil Therapeutics plans to initiate a first-in-human studies in 2027
06 Nov 2025 Mwyngil Therapeutics in-licenses GPR75 modulators and cell-surface discovery platform from Expert Systems
06 Nov 2025 Preclinical trials in Obesity in USA (unspecified route)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com